Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

A combinatorial feature selection approach to describe the QSAR of dual site inhibitors of acetylcholinesterase.

Asadabadi EB, Abdolmaleki P, Barkooie SM, Jahandideh S, Rezaei MA.

Comput Biol Med. 2009 Dec;39(12):1089-95. doi: 10.1016/j.compbiomed.2009.09.003. Epub 2009 Oct 24.

PMID:
19854437
2.
3.
4.
5.

Design and synthesis of dual inhibitors of acetylcholinesterase and serotonin transporter targeting potential agents for Alzheimer's disease.

Kogen H, Toda N, Tago K, Marumoto S, Takami K, Ori M, Yamada N, Koyama K, Naruto S, Abe K, Yamazaki R, Hara T, Aoyagi A, Abe Y, Kaneko T.

Org Lett. 2002 Oct 3;4(20):3359-62.

PMID:
12323018
6.
7.

Molecular docking and receptor-specific 3D-QSAR studies of acetylcholinesterase inhibitors.

Deb PK, Sharma A, Piplani P, Akkinepally RR.

Mol Divers. 2012 Nov;16(4):803-23. doi: 10.1007/s11030-012-9394-x. Epub 2012 Sep 21.

PMID:
22996404
10.

Receptor-dependent (RD) 3D-QSAR approach of a series of benzylpiperidine inhibitors of human acetylcholinesterase (HuAChE).

Araújo JQ, de Brito MA, Hoelz LV, de Alencastro RB, Castro HC, Rodrigues CR, Albuquerque MG.

Eur J Med Chem. 2011 Jan;46(1):39-51. doi: 10.1016/j.ejmech.2010.10.009. Epub 2010 Oct 15.

PMID:
21074294
11.

Construction of the pharmacophore model of acetylcholinesterase inhibitor.

Zhu Y, Tong XY, Zhao Y, Chen H, Jiang FC.

Yao Xue Xue Bao. 2008 Mar;43(3):267-76.

PMID:
18630262
12.

QSAR studies on N-aryl derivative activity towards Alzheimer's disease.

Solomon KA, Sundararajan S, Abirami V.

Molecules. 2009 Apr 7;14(4):1448-55. doi: 10.3390/molecules14041448.

13.

Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease.

Muñoz-Ruiz P, Rubio L, García-Palomero E, Dorronsoro I, del Monte-Millán M, Valenzuela R, Usán P, de Austria C, Bartolini M, Andrisano V, Bidon-Chanal A, Orozco M, Luque FJ, Medina M, Martínez A.

J Med Chem. 2005 Nov 17;48(23):7223-33.

PMID:
16279781
14.

Discovery of dual binding site acetylcholinesterase inhibitors identified by pharmacophore modeling and sequential virtual screening techniques.

Gupta S, Fallarero A, Järvinen P, Karlsson D, Johnson MS, Vuorela PM, Mohan CG.

Bioorg Med Chem Lett. 2011 Feb 15;21(4):1105-12. doi: 10.1016/j.bmcl.2010.12.131. Epub 2011 Jan 1.

PMID:
21273074
15.
16.

QSAR applications during last decade on inhibitors of acetylcholinesterase in Alzheimer's disease.

Wong KY, Duchowicz PR, Mercader AG, Castro EA.

Mini Rev Med Chem. 2012 Sep 1;12(10):936-46. Review.

PMID:
22303974
17.

Receptor-based modeling and 3D-QSAR for a quantitative production of the butyrylcholinesterase inhibitors based on genetic algorithm.

Zaheer-ul H, Uddin R, Yuan H, Petukhov PA, Choudhary MI, Madura JD.

J Chem Inf Model. 2008 May;48(5):1092-103. doi: 10.1021/ci8000056. Epub 2008 Apr 29.

PMID:
18444627
18.

Ligand-based 3D-QSAR studies of physostigmine analogues as acetylcholinesterase inhibitors.

Ul-Haq Z, Mahmood U, Jehangir B.

Chem Biol Drug Des. 2009 Dec;74(6):571-81. doi: 10.1111/j.1747-0285.2009.00897.x. Epub 2009 Oct 15.

PMID:
19843075
19.

Structure-based 3D QSAR and design of novel acetylcholinesterase inhibitors.

Sippl W, Contreras JM, Parrot I, Rival YM, Wermuth CG.

J Comput Aided Mol Des. 2001 May;15(5):395-410.

PMID:
11394735
20.

3D-QSAR analysis of a new type of acetylcholinesterase inhibitors.

Liu A, Guang H, Zhu L, Du G, Lee SM, Wang Y.

Sci China C Life Sci. 2007 Dec;50(6):726-30. Epub 2007 Oct 4.

PMID:
17914643
Items per page

Supplemental Content

Write to the Help Desk